Randomized trial of gemcitabine plus docetaxel vs. docetaxel plus capecitabine in metastatic breast cancer in 1st and 2nd line patients.

Trial Profile

Randomized trial of gemcitabine plus docetaxel vs. docetaxel plus capecitabine in metastatic breast cancer in 1st and 2nd line patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2014

At a glance

  • Drugs Capecitabine; Docetaxel; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Nov 2008 Status changed from active, no longer recruiting to completed.
    • 27 Dec 2007 The expected completion date for this trial is now Jun 2008 according to ClinicalTrials.gov.
    • 06 Sep 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top